Dieser Anti-RSV (Palivizumab Biosimilar) Antikörper ist ein Humanized Monoklonal Antikörper zur Detektion von RSV (Palivizumab Biosimilar) in FACS und in vivo. Geeignet für Human.
Produktnummer ABIN7200664
Kurzübersicht für Rekombinanter RSV (Palivizumab Biosimilar) Antikörper (ABIN7200664)
Target
RSV (Palivizumab Biosimilar)
Antikörpertyp
Recombinant Antibody
Reaktivität
Human
Wirt
Humanized
Klonalität
Monoklonal
Konjugat
Dieser RSV (Palivizumab Biosimilar) Antikörper ist unkonjugiert
Applikation
Flow Cytometry (FACS), In vivo Studies (in vivo)
Güteklasse
Research Grade
Verwendungszweck
Palivizumab Biosimilar, RSV Monoclonal Antibody
Spezifität
The monoclonal antibody palivizumab biosimilar specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus).
Produktmerkmale
Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.
Aufreinigung
Protein A or G affinity column
Reinheit
>95 % by reducing SDS-PAGE
Sterilität
0.2 μm filtered
Endotoxin-Niveau
< 1 EU per 1 mg of the protein by the LAL method
Immunogen
The monoclonal antibody palivizumab biosimilar was produced in the palivizumab biosimilar CHO stable cell line.
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by palivizumab.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
> 3 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Konservierungsmittel
Without preservative
Lagerung
4°C,-20 °C
Informationen zur Lagerung
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.